DOI QR코드

DOI QR Code

No Association Between the GSTM1 Null Genotype and Risk of Renal Cell Carcinoma: A Meta-analysis

  • Liu, Rui (Department of Oncology, Suining Central Hospital) ;
  • Wang, Xiao-Hua (Department of Oncology, Suining Central Hospital) ;
  • Liu, Li (Department of Oncology, Suining Central Hospital) ;
  • Zhou, Qiang (Department of Oncology, Suining Central Hospital)
  • 발행 : 2012.07.31

초록

Background: Many studies have focused on possible associations between the glutathione S-transferase M 1 (GSTM1) null genotype and risk of renal cell carcinoma (RCC), but the impact remains unclear owing to obvious inconsistencies among the findings. The present study aimed to quantify the strength of any association in a meta-analysis. Methods: We searched the PubMed, Embase and CBM databases for studies concerning the association between the GSTM1 null genotype and risk of RCC. We estimated the summary odds ratio (OR) with its 95% confidence intervals (95% CI) to assess the association. Results: The meta-analysis showed the GSTM1 null genotype was not associated with risk of RCC overall (OR = 1.04, 95% CI 0.92-1.18, P = 0.501). For Caucasians, the GSTM1 null genotype was also not associated with risk of RCC (OR=1.02, 95% CI 0.90-1.16, P = 0.761). The cumulative meta-analyses showed a trend of no obvious association between GSTM1 null genotype and risk of RCC as information accumulated. Sensitivity analyses by omitting those studies also did not materially alter the overall combined ORs. No evidence of publication bias was observed. Conclusion: Meta-analyses of available data show that the GSTM1 null genotype is not significantly associated with risk of renal cell carcinoma.

키워드

참고문헌

  1. Ahmad ST, Arjumand W, Seth A, et al (2012). Impact of glutathione transferase M1, T1, and P1 gene polymorphisms in the genetic susceptibility of North Indian population to renal cell carcinoma. DNA Cell Biol, 31, 636-43. https://doi.org/10.1089/dna.2011.1392
  2. Attia J, Thakkinstian A, D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol, 56, 297-303. https://doi.org/10.1016/S0895-4356(03)00011-8
  3. Bex A, Gore M, Mulders P, et al (2012). Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. BJU Int, [Publishing in progress].
  4. Bruning T, Lammert M, Kempkes M, et al (1997). Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol, 71, 596-9. https://doi.org/10.1007/s002040050432
  5. Buzio L, De Palma G, Mozzoni P, et al (2003). Glutathione S-transferases M1-1 and T1-1 as risk modifiers for renal cell cancer associated with occupational exposure to chemicals. Occup Environ Med, 60, 789-93. https://doi.org/10.1136/oem.60.10.789
  6. Chen J, Cheng M, Yi L, et al (2011). Relationship between CYP1A1 genetic polymorphisms and renal cancer in China. Asian Pac J Cancer Prev, 12, 2163-6.
  7. De Martino M, Klatte T, Schatzl G, et al (2010). Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene. J Urol, 183, 878-83. https://doi.org/10.1016/j.juro.2009.11.032
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  9. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  10. Hayes JD, Flanagan JU, Jowsey IR (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol, 45, 51-88. https://doi.org/10.1146/annurev.pharmtox.45.120403.095857
  11. Hayes JD, Strange RC (2000). Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology, 61, 154-66. https://doi.org/10.1159/000028396
  12. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  13. Jonasch E, Futreal A, Davis I, et al (2012). State-of-the-science: An update on renal cell carcinoma. Mol Cancer Res, [Publishing in progress].
  14. Kumar V, Murthy AK, Suresh KP (2011). Glutathione S-transferase M1 and T1 status and the risk of laryngeal cancer: a meta-analysis. Asian Pac J Cancer Prev, 12, 2221-6.
  15. Liu Y, Xu LZ (2012). Meta-analysis of association between GSTM1 gene polymorphism and cervical cancer. Asian Pac J Trop Med, 5, 480-4. https://doi.org/10.1016/S1995-7645(12)60083-2
  16. Longuemaux S, Delomenie C, Gallou C, et al (1999). Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res, 59, 2903-8.
  17. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  18. Moore LE, Brennan P, Karami S, et al (2007). Glutathione S-transferase polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study. Carcinogenesis, 28, 1960-4. https://doi.org/10.1093/carcin/bgm151
  19. Muellerleile P, Mullen B (2006). Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health, 96, 515-22. https://doi.org/10.2105/AJPH.2003.036343
  20. Murai M, Oya M (2004). Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol, 14, 229-33. https://doi.org/10.1097/01.mou.0000135078.04721.f5
  21. Petitti DB (2000) Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine(2nd ed). New York, NY: Oxford University Press.
  22. Salinas-Sanchez AS, Sanchez-Sanchez F, Donate-Moreno MJ, et al (2012). GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer. Urol Oncol, [Publishing in progress].
  23. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  24. Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, et al (2009). Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol, 6, 281-9. https://doi.org/10.1038/nrurol.2009.49
  25. Sweeney C, Farrow DC, Schwartz SM, et al (2000). Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev, 9, 449-54.
  26. Wang B, Huang G, Wang D, et al (2010). Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol, 53, 508-18. https://doi.org/10.1016/j.jhep.2010.03.026
  27. Zhang R, Xu G, Chen W, et al (2011). Genetic polymorphisms of glutathione S-transferase M1 and bladder cancer risk: a meta-analysis of 26 studies. Mol Biol Rep, 38, 2491-7. https://doi.org/10.1007/s11033-010-0386-6
  28. Zhu Y, He Q, Wang J, et al (2012). The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis. Mol Biol Rep, 39, 685-91. https://doi.org/10.1007/s11033-011-0786-2
  29. Zintzaras E, Lau J (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 61, 634-45. https://doi.org/10.1016/j.jclinepi.2007.12.011

피인용 문헌

  1. Combined GSTM1-Null, GSTT1-Active, GSTA1 Low-Activity and GSTP1-Variant Genotype Is Associated with Increased Risk of Clear Cell Renal Cell Carcinoma vol.11, pp.8, 2016, https://doi.org/10.1371/journal.pone.0160570
  2. GSTM1 and GSTT1 polymorphisms contribute to renal cell carcinoma risk: evidence from an updated meta-analysis vol.5, pp.1, 2015, https://doi.org/10.1038/srep17971
  3. A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility vol.19, pp.1, 2018, https://doi.org/10.1186/s12881-018-0620-y